时珍国医国药2026，Vol.37Issue(4)：623-633,11.DOI:10.70976/j.1008-0805.SZGYGY-2026-0404
玉屏风散加味方的胚胎毒性评估及多模态炎症调控作用研究
Evaluation of embryotoxicity and multimodal anti-inflammatory effects of Jiawei Yupinfeng Powder(玉屏风散加味方)in a zebrafish model
摘要
Abstract
Objective To evaluate the embryotoxicity and multimodal anti-inflammatory effects of Jiawei Yupinfeng Powder(玉屏风散加味方,JYP)using a zebrafish model.Methods Zebrafish embryos were continuously exposed to JYP at concentrations ranging from 50 to 1600 µg/mL to monitor its acute toxicity on 14 endpoints,including embryonic development,cardiac function,liver metabolism,and renal excretion.Multimodal inflammation models induced by CuSO4,tail transection,and lipopolysaccharide(LPS)were established.The effects of JYP on neutrophil infiltration,nitric oxide(NO)levels,and the mRNA expression of key inflammatory factors(NLRP3,Caspase-1,IL-1β,TNF-α,IL-4)were then analyzed.Results The LC50 of JYP was 1192 µg/mL.No significant toxicity was observed at concentrations of 50-400 µg/mL.However,higher concentrations caused embryonic developmental abnormalities and cardiotoxicity.Treatment with JYP significantly inhibited neutrophil infiltration(P<0.01),modulated NO levels(P<0.01),and downregulated the mRNA expression of NLRP3,Caspase-1,IL-1β,TNF-α,and IL-4(P<0.01).Conclusion The LC50 of JYP was 1192 µg/mL,with an embryo-safe concentration of≤400 µg/mL.Higher concentrations may induce developmental toxicity and cardiotoxicity.The anti-inflammatory effects of JYP likely involve multi-target mechanisms:inhibiting the NLRP3 inflammasome pathway(NLRP3,Caspase-1),reducing pro-inflammatory mediators(TNF-α,IL-1β),and modulating the Th2-type immune response(IL-4).This synergistic action suggests a bidirectional immunomodulatory property,mitigating excessive inflammation while promoting immune homeostasis.关键词
玉屏风散加味方/胚胎毒性/炎症/脂多糖/斑马鱼模型Key words
Jiawei Yupinfeng Powder(玉屏风散加味方)/Embryotoxicity/Inflammation/Lipopolysaccharide/Zebrafish model分类
医药卫生引用本文复制引用
钟楚婷,周萍,雷晓椿,刘建廷,陈清韵,王佳璇,张丽娟,李得堂..玉屏风散加味方的胚胎毒性评估及多模态炎症调控作用研究[J].时珍国医国药,2026,37(4):623-633,11.基金项目
国家自然科学基金面上项目(82374526) （82374526）
广州市科技计划项目市校(院)联合资助项目(2023A03J0299) （院）
邱宝珊教授广东省名中医传承工作室项目(粤中医办函[2023]108号) （粤中医办函[2023]108号）
广东省第四批名中医师承项目(粤中医办函[2023]108号) （粤中医办函[2023]108号）
药食同源儿童健康食品创新团队项目(云科函[2022]16号) （云科函[2022]16号）
